Paul Williams serves as Senior Vice President, Products Business at Emergent BioSolutions Inc., where he leads the strategic direction and commercial execution for the company's expansive portfolio of vaccines, therapeutics, and medical countermeasures. With over 25 years of experience in the biopharmaceutical industry, Williams has established himself as a visionary leader in product commercialization, supply chain optimization, and market expansion for critical public health solutions. His tenure at Emergent has been marked by driving revenue growth through innovative partnerships and accelerating the delivery of life-saving products amid global health crises. Prior to joining Emergent in 2018, Williams held progressive leadership roles at GlaxoSmithKline and Pfizer, where he spearheaded the launch of blockbuster vaccines and biologics, generating billions in annual sales. Notable achievements include leading the U.S. commercialization of a novel shingles vaccine at GSK, which captured over 60% market share within two years, and optimizing global supply chains at Pfizer during the H1N1 pandemic response. Williams holds a Bachelor of Science in Biochemistry from the University of Michigan and an MBA from the Wharton School, complementing his deep scientific and business acumen. In his current role, Williams oversees a dynamic team focused on enhancing Emergent's position as a trusted partner to government agencies and healthcare providers. He has been instrumental in expanding the company's product pipeline, including advancements in anthrax countermeasures and opioid therapeutics, while fostering sustainable growth strategies that align with Emergent's mission to protect global health security. Under his guidance, the Products Business unit has achieved record milestones in production scalability and regulatory approvals, positioning Emergent for continued leadership in biodefense and infectious disease preparedness.